|
|
|||
| |||||||||||||||||||||||||||||||||
-thalassemia intermedia, the hematologic response to hydroxyurea alone or in combination with recombinant human erythropoietin is controversial,3,4,5 and little is known about the effectiveness of long-term therapy. The standard therapeutic approach to
-thalassemia major still relies on regular blood transfusions and the use of iron chelators. In this report, we describe the clinical and hematologic response of a 20-year-old man with transfusion-dependent
0References
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |